Tofisopam: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 24: | Line 24: | ||
[[Category:Anxiolytics]] | [[Category:Anxiolytics]] | ||
[[Category:Benzodiazepines]] | [[Category:Benzodiazepines]] | ||
<gallery> | |||
File:Tofisopam structure.svg|Tofisopam structure | |||
File:Tofisopam ball-and-stick model.png|Tofisopam ball-and-stick model | |||
</gallery> | |||
Latest revision as of 01:09, 20 February 2025
Tofisopam is a benzodiazepine derivative with unique properties. Unlike most benzodiazepines, it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing or amnestic properties. It is primarily anxiolytic and acts as a serotonin antagonist and dopamine agonist.
Pharmacology[edit]
Tofisopam is a 2,3-benzodiazepine, which has a unique profile of pharmacological activity compared to the 1,4-benzodiazepines. It is a selective anxiolytic, without sedative, muscle relaxant, or anticonvulsant effects. Tofisopam also has anti-aggressive properties and enhances serotonin turnover in the brain.
Medical uses[edit]
Tofisopam is used for the treatment of anxiety disorders and for short-term relief of the symptoms of anxiety. It is also used to treat irritable bowel syndrome and to help manage alcohol withdrawal syndrome.
Side effects[edit]
The most common side effects of Tofisopam are dizziness, headache, and gastrointestinal disturbances. Rare side effects include skin rash, changes in libido, and mood changes.
History[edit]
Tofisopam was first synthesized in the 1960s by the Hungarian pharmaceutical company Egis Pharmaceuticals. It is marketed in several countries worldwide, including Hungary, Japan, India, and some countries in Europe.
See also[edit]
-
Tofisopam structure
-
Tofisopam ball-and-stick model
